Replies to post #1121 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I have been wondering for much longer why nobody sees the value of this company.<

Some people do :-)

>It seems nowadays that if there is no immediate revenue there is no shareholders’ interest.<

Investor fashion can change abruptly. Alternative production platforms could be all the rage a year from now.

Moreover, drug companies themselves are paying attention to this arena, as evidenced by MRK’s acquisition of GlycoFi for $400M.

My advice is to take a breather from watching the tape. If the fundamentals are strong, the share price will take care of itself in due course.

[jessellivermore]

IMHO the reason GTCB's pps has remained in the cellar has more to do with it's past history of mind crunching disappointments, including the EMEA's recent negative opinion. Note the level of enthusiasm for the stock (pps) has not risen to the pre opinion level.

The LFB "dilution" is largely an illusion with little chance of ever showing up in the float. So worrying about it does not make much sense. The "shares" are a vehicle to provide LFB representation in GTCB. LFB needs GTCB.

Stocks climb a wall of fear. The momentum is buiding to overcome the fear created by past failures. This momentum is being provided by genuine improvement in GTCB's finances, it's connections and most importantly by the recognition it is
receveiving from its own industry.